Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

1.3K
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
1.3K
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

765
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
765
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

1.3K
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
1.3K
Desensitization and Tachyphylaxis01:20

Desensitization and Tachyphylaxis

2.9K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
2.9K
Drug Therapy01:28

Drug Therapy

229
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
229
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

598
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
598

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Moderate to severe negative symptoms predict low risk of symptoms worsening in schizophrenia patients in CATIE.

Schizophrenia research·2026
Same author

Modeling Negative Symptom Domain Neurobiology: Protocol for an Observational, Transdiagnostic, Translational Study.

JMIR research protocols·2026
Same author

Why Psychiatric Services Need Philosophical Literacy.

Psychiatric services (Washington, D.C.)·2026
Same author

Antipsychotic deprescribing as a problem of care, not compliance.

Schizophrenia (Heidelberg, Germany)·2026
Same author

Recognizing epistemic injustice in healthcare: a case for methodological pluralism.

Medicine, health care, and philosophy·2026
Same author

Professional Accountability and Responsibility in an Era of Self-Diagnosis and Radical Subjectivity.

Psychiatric services (Washington, D.C.)·2026

Related Experiment Video

Updated: Jan 7, 2026

Conventional Repetitive Transcranial Magnetic Stimulation for Depression: A Step-by-Step Protocol
10:54

Conventional Repetitive Transcranial Magnetic Stimulation for Depression: A Step-by-Step Protocol

Published on: November 21, 2025

224

[Principles of antidepressant tapering].

Marte Ustrup1, Casper Westergaard2, Helene Speyer1,3

  • 1Copenhagen Research Center for Mental Health (CORE), Psykiatrisk Center København, Region Hovedstadens Psykiatri.

Ugeskrift for Laeger
|January 5, 2026
PubMed
Summary

Discontinuing antidepressants requires careful planning due to frequent and severe withdrawal symptoms. A slow, hyperbolic tapering process, as outlined in the Maudsley Deprescribing Guidelines, can significantly reduce these risks.

More Related Videos

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

493
Treating Clinical Depression with Repetitive Deep Transcranial Magnetic Stimulation Using the Brainsway H1-coil
09:30

Treating Clinical Depression with Repetitive Deep Transcranial Magnetic Stimulation Using the Brainsway H1-coil

Published on: October 4, 2016

22.8K

Related Experiment Videos

Last Updated: Jan 7, 2026

Conventional Repetitive Transcranial Magnetic Stimulation for Depression: A Step-by-Step Protocol
10:54

Conventional Repetitive Transcranial Magnetic Stimulation for Depression: A Step-by-Step Protocol

Published on: November 21, 2025

224
Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

493
Treating Clinical Depression with Repetitive Deep Transcranial Magnetic Stimulation Using the Brainsway H1-coil
09:30

Treating Clinical Depression with Repetitive Deep Transcranial Magnetic Stimulation Using the Brainsway H1-coil

Published on: October 4, 2016

22.8K

Area of Science:

  • Neuroscience
  • Clinical Pharmacology
  • Psychiatry

Background:

  • Antidepressant discontinuation is complex, with limited guidance on tapering.
  • Withdrawal symptoms are often underestimated in frequency, severity, and duration.

Purpose of the Study:

  • To present the principles of slow, hyperbolic tapering for antidepressant discontinuation.
  • To highlight updated guidelines for managing antidepressant withdrawal.

Main Methods:

  • Review of the Maudsley Deprescribing Guidelines.
  • Analysis of neurobiological mechanisms and risk profiles associated with antidepressant cessation.

Main Results:

  • Withdrawal symptoms are more common, severe, and prolonged than previously thought.
  • A hyperbolic tapering schedule is proposed to mitigate these risks.

Conclusions:

  • Antidepressant tapering requires a nuanced approach beyond current guidelines.
  • Implementing slow, hyperbolic tapering can improve patient safety and reduce discontinuation challenges.